EurekAlert! Cancer Research - News Releases

News Releases

Updates every hour. Last Updated: 13-May-2025 15:09 ET (13-May-2025 19:09 GMT/UTC)

Candidate genes in canine hepatocellular carcinoma for molecular targeted therapy

Osaka Metropolitan University
Peer-Reviewed Publication

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the expression of target genes. Therefore, the efficacy of the targeted therapies for canine HCC remains unclear.

Journal: BMC Research Notes
Funder: Japan Society for the Promotion of Science

New research uncovers hidden rules of immune response, opening doors for better vaccines and immunotherapies

Institute for Systems Biology
Peer-Reviewed Publication

Scientists at the Institute for Systems Biology (ISB) have uncovered key insights into how T cells – the body's frontline immune soldiers – respond to infections like COVID-19. These findings could help scientists refine immune response strategies to improve long-term protection against diseases. Furthermore, these insights could contribute to more precise treatments for cancer and autoimmune diseases.

Journal: Nature Communications

Breast cancers broadly defined by their genome architecture in Stanford Medicine study

Stanford Medicine
Peer-Reviewed Publication

Breast cancers at all stages are defined by the structure of their genomes, Stanford Medicine researchers find. Targeting these processes early is likely to offer unexpected therapeutic avenues.

Journal: Nature

Co-located cell types help drive aggressive brain tumors

Johns Hopkins Medicine
Peer-Reviewed Publication

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research led by investigators at the Johns Hopkins Kimmel Cancer Center Bloomberg~Kimmel Institute for Cancer Immunotherapy and the Johns Hopkins University School of Medicine.

Journal: Science
Funder: NIH/National Institutes of Health, NIH/National Institutes of Health, NIH/National Institutes of Health, NIH/National Institutes of Health, NIH/National Institutes of Health, Neurosurgery Research Education Foundation, Bloomberg~Kimmel Institute for Cancer Immunotherapy, Mark Foundation For Cancer Research, Burroughs Wellcome Career Award for Medical Scientists, Commonwealth Foundation, Maryland Cigarette Restitution Fund and the NIH Pioneer Award

JMC | Insilico Medicine unveils novel AI-driven FGFR2/3 inhibitor to overcome resistance tumor mutations

InSilico Medicine
Peer-Reviewed Publication

Recently, Insilico Medicine (“Insilico”) announces that the team, with the support of its generative chemistry engine, has developed a novel and highly selective FGFR2/3 dual inhibitor, which maintains efficacy against resistance mutations, shows potency in gastric cancer animal model, and demonstrates a more favorable safety profile compared to existing FGFR inhibitors. The findings have been published in the Journal of Medicinal Chemistry (JMC, IF=7.2)

Journal: Journal of Medicinal Chemistry

Team of Prof. Woo Young Jang Department of Orthopedic Surgery, KU Anam Hospital wins the Best Paper Award from the Korean Musculoskeletal Tumor Society

Korea University College of Medicine
Grant and Award Announcement

Professor Woo Young Jang (Department of Orthopedic Surgery, Korea University Anam Hospital) recently won the best paper award at the 2024 fall academic conference of the Korean Musculoskeletal Tumor Society. This award recognizes the outstanding results and academic value of the research led by Professor Jang.

Electronic reporting of symptoms by cancer patients can improve quality of life and reduce emergency visits

University of North Carolina Health Care
Peer-Reviewed Publication

People with metastatic cancer who regularly report their symptoms via a home-based electronic monitoring system experienced improved quality of life, clinical outcomes and well-being, as well as fewer emergency department visits than those who didn’t file reports.

Journal: Nature Medicine
Funder: Patient-Centered Outcomes Research Institute

Researchers unveil a novel strategy to combat melanoma brain metastases

Universidad Miguel Hernandez de Elche
Peer-Reviewed Publication

This study reveals the key role of microglia, brain’s immune cells, in brain metastases progression and identifies a strategy to manipulate them to promote antitumor responses.

This finding, published in Cancer Cell, could enhance the effectiveness of immunotherapy in patients with brain metastases.

A new study reveals the key role of microglia, brain’s immune cells, in brain metastases progression and identifies a strategy to manipulate them to promote antitumor responses. This finding, published in Cancer Cell, could enhance the effectiveness of immunotherapy in patients with brain metastases.

Journal: Cancer Cell
Funder: Agencia Estatal de Investigación, Agencia Estatal de Investigación, Agencia Estatal de Investigación, Instituto de Salud Carlos III, FERO Foundation, Melanoma Research Alliance, Generalitat Valenciana, Generalitat Valenciana, Generalitat Valenciana, Consejo Superior de Investigaciones Científicas, Agencia Estatal de Investigación

Researchers discover anti-cancer potential of immune modulator's short form

Chinese Academy of Sciences Headquarters
Peer-Reviewed Publication

Prof. MENG Guangxun's team from the Shanghai Institute of Immunity and Infection of the Chinese Academy of Sciences, and collaborators, have revealed a novel mechanism whereby a short form of IL-18, generated by caspase-3 cleavage in tumor cells, activates natural killer (NK) cells to suppress tumor growth, offering new therapeutic opportunities.

Journal: Nature Immunology

Personalized cancer treatment using 3D bioprinting technology

Pohang University of Science & Technology (POSTECH)
Peer-Reviewed Publication

POSTECH and The Jackson Laboratory, Developing an In Vitro Platform to Evaluate and Predict Drug Responses in Gastric Cancer Patients.

Journal: Advanced Science